Introduction
Mitochondria contain the only extra-nuclear source of DNA. Under evolutionary pressure mitochondrial DNA (mtDNA) has adapted from genomes containing over 1,000 kb containing significant quantities of non-coding DNA to the highly compact mammalian mtDNA. In humans, the mitochondrial genome consists of a small (16.5 kb) double-stranded circular genome constituting less than 1% of the total cellular nucleic acid, yet its role is essential for the survival and function of the mitochondria and hence the cell (Fig. 1) . Human mtDNA is a highly efficient structure in terms of expressed DNA containing no introns. It encodes for 37 genes, all of which are involved in synthesising subunits of the respiratory chain complex, either directly as 13 essential polypeptide components, or indirectly as the 22 transfer RNAs and the 2 ribosomal RNAs of the mitochondrial protein synthesis machinery (Fig. 1b) . Human cells contain several hundred to many thousand mitochondria, with each mitochondrion having 2-10 copies of mtDNA [1] . Therefore several thousand copies of mtDNA can be present within a single cell. Both mutated and wild-type (normal) mtDNA can co-exist in any proportion, a situation termed heteroplasmy. The level of mutant mtDNA can vary considerably between mitochondria, cells and even tissues within the same individual.
The mitochondrial genome mutates at a faster rate than its nuclear counterpart for several reasons. Firstly mitochondria lack nucleotide excision and recombination DNA repair mechanisms [2] . Secondly mtDNA lacks the structurally DNA stabilising proteins known as histones. Thirdly mtDNAs reside and replicate close to the inner mitochondrial membrane and hence are exposed to the enriched free radical milieu produced by both the respiratory chain and monoamine oxidases located within the membrane. These free radicals can cause oxidative damage and promote mutations [3] . Over the past two decades the role of mtDNA mutations in causing hereditary disease in humans has become well described, with over 100 pathological mtDNA defects having been characterised [4] . These alterations in the mtDNA can occur either as point mutations involving the tRNA or protein encoding genes, or rearrangements in the form of deletions or duplications. In the presence of heteroplasmy there appears to be a critical ratio of mutant to wild-type mtDNA that is necessary before disease becomes both clinically and biochemically apparent. Whilst this threshold level appears to be dependent upon both the nature of the mutation and the tissue affected, the vast majority of pathological mtDNA tRNA mutations that have been investigated are extremely recessive with biochemical dysfunction only becoming apparent when levels of the mutant mtDNA exceed 60-70%.
Harman [5] in 1972 was amongst the first to suggest that mitochondria may play a role in the physiology of aging. Linnane et al. [6] in 1989 further helped expand this theory by suggesting that a chronological increase in mtDNA mutations may be partly responsible for the biological features seen with aging. Since this time evidence has rapidly accumulated to suggest that damage to mitochondria and mtDNA does indeed occur with normal aging and in even greater quantities in certain age-dependent neurodegenerative disorders. This has prompted the theory that mtDNA mutations may also play a primary role in the neuronal loss characterised by these disorders.
In this review we will briefly discuss hereditary mtDNA disorders. We then outline some of the evidence showing that mitochondria play a role in the aging process and give a brief synopsis of the recent developments we have made into aging and age-related neurodegenerative disorders.
Hereditary Mitochondrial DNA Disorders
It is now well established that inherited or spontaneous mtDNA defects can cause clinical disease. Alterations in the mtDNA can occur either as point mutations involving the tRNA or protein-encoding genes, or rearrangements in the form of deletions or duplications. In the presence of heteroplasmy there is a critical ratio of mutant to wild-type mtDNA that is necessary before the disease can become both biochemically and clinically apparent. Whilst this threshold level is variable, depending upon both the nature of the mutation and the tissue affected, the vast majority of pathological mtDNA tRNA mutations investigated are extremely recessive and biochemical dysfunction is only apparent with levels of <30% of wild-type mtDNA.
The Mitochondrial Genome, Aging and Neurodegenerative Disorders MtDNA disorders are phenotypically diverse and as might be expected given the ubiquitous presence of mitochondria and the variation in levels of heteroplasmy throughout the body are multi-system in nature (Fig. 1c) . However, many mtDNA disorders feature predominantly neurological and muscular symptoms that progress temporally, including seizures, ataxic syndromes, dementia, peripheral neuropathies and myopathy. This is probably due to the post-mitotic nature of the CNS and muscle with the concurrent higher levels of mutant mtDNA than in mitotic tissues. CNS imaging of patients with mtDNA disorders often reveals moderate degrees of cerebral or cerebellar atrophy that is consistent with neurodegeneration and are often comparable with senescent brains. Limited neuropathological studies have confirmed massive neuronal cell loss and demyelination [7, 8] .
We believe that further investigation into the pathogenic mechanisms involved in these mtDNA disorders will help in our understanding of the role of defects of mitochondrial function in aging. Therefore we have examined the CNS of a patient with a multiple mtDNA deletion disorder both histochemically and neuropathologically and correlated the degree of mitochondrial enzyme deficiency with the degree of neurodegeneration [9] . In general we found a paradoxical decrease in the percentage of neurons containing a biochemical mitochondrial enzyme deficiency in the CNS regions exhibiting the most marked neuronal loss. We hypothesised that certain neuronal populations have a lower tolerance to defects in the oxidative phosphorylation pathway and hence a reduction in the ability to synthesise ATP. These neurons may then undergo neurodegeneration that would explain the apparent paradox in the CNS regions with high neuronal loss but low levels of mitochondrial enzymedeficient neurons. In contrast the regions without significant neuronal loss with higher numbers of mitochondrial enzyme-deficient neurons may have neuronal populations relatively more resistant to loss of oxidative phosphorylation activity.
Multiple mtDNA deletion disorders are of particular relevance to the theory that accumulating mtDNA mutations may participate in aging. In this type of mtDNA disorder the inherited defect is thought to actually reside in the nuclear genome. This nuclear mutation somehow causes instability in the mitochondrial genome resulting in the accelerated accumulation of mtDNA deletion-type mutations providing the ideal case to examine for pathological markers of aging. Indeed, in addition to the marked neuronal loss, this case also showed high levels of Biondi bodies, cytoplasmic thread-like structures with similar staining properties to amyloid found in choroid plexus epithelial cells [10] . These Biondi bodies are a consistent neuropathological marker of aging, accumulating with normal aging [11, 12] and in even greater quantities in Alzheimer's disease (AD) [13] . This case of a 50-year-old with a multiple mtDNA deletion disorder had levels consistent with that seen in a normal case in their 80s with AD, despite the fact that he had not demonstrated any significant dementia.
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Changes in Mitochondria with Age
Mitochondria have been shown to become larger and less numerous with vacuolisation in aging organisms. Abnormalities in the cristae structure and the accumulation of intra-mitochondrial paracrystalline inclusions also appear [14, 15] . Cardiolipin, an acidic phospholipid which is unique to mitochondria, has also been shown to decrease with age [16] [17] [18] . This inner membrane lipid has excellent electrical insulating properties and is believed to contribute significantly to the transmembrane potential, which drives the formation of ATP via ATP synthase, the terminal complex of the respiratory chain. Physiological studies have shown that there is a decrease in membrane potential in mitochondria from older animals [19, 20] .
In addition mitochondria and mtDNA are particularly vulnerable to oxidative damage. Their high consumption of metabolic fuels, in the pursuit of ATP production via the inner membrane-incorporated respiratory chain, releases the toxic by-products known as free radicals [21] . Free radical-scavenging enzymes such as superoxide dismutase and catalase normally dispose of these highly unstable molecules. During aging some of these free radical-scavenging systems are decreased [22] so that more free radicals escape, thus increasing the level of oxidative stress within the organelle. These free radicals can oxidise membrane lipids in close proximity to the respiratory chain, which decreases the fluidity and increases the permeability of the inner mitochondrial membrane. Oxidation of mitochondrial proteins and DNA also occurs. Oxidatively damaged proteins are known to increase markedly with age [23] , the role of which has long been questioned. It was assumed that any damaged protein would not accumulate, as cellular proteins are continuously overturned and damaged proteins more rapidly than normal. However, functionally inactive forms of enzymes have been shown to accumulate with age and are thought to be a result of oxygen free radical-mediated damage. An age-related increase in the amount of oxidised protein is possibly the result of an accumulation of damage to DNA, which affects the factors responsible for protein oxidation, and the degradation of oxidised protein [23] . An accumulation of oxidised protein may also result in cross-linking to other proteins, which would alter their biochemical and physiological function in mitochondria.
Levels of the oxidised nucleotide 8-hydroxy-deoxyguanosine (8-OH-dG), a biomarker of DNA damage, has also been shown to accumulate with aging. In several tissues, including the CNS and muscle, levels of 8-OH-dG in mtDNA exceed those in nuclear DNA (nDNA) by some 16-fold [2] . Several studies indicate that 8-OH-dG most frequently encodes correctly for cytosine but also has the ability to pair with adenine approximately 1% of the time [24] ; it also has the ability to cause misreading at adjacent residues. Hayakawa et al. [25] found that increased levels of 8-OH-dG in human heart correlated with increases in levels of a 7.4-kB deletion, and Mecocoi et al. [26] found a similar correlation in human brain.
Mitochondrial DNA Mutations Accumulate with Age
Although compact and efficient, the human mitochondrial genome is also a particularly vulnerable piece of DNA to mutations. Not only does it lack introns, which means that almost all mutations will be in encoding regions but it is also believed to have a 10-fold higher mutation rate than nuclear DNA [2, 3, 27] for reasons already discussed.
Substantial evidence has emerged demonstrating that mtDNA mutations increase temporally with the highest levels seen in the post-mitotic CNS and muscle. To date over 20 different types of deletions have been shown to accumulate in aging human tissues. The first published report of an age-related increase in a mtDNA deletion was the so-called common deletion found in elderly brain tissue and patients with Parkinson's disease [28] . The common deletion occurs between two 13-bp sequence repeats beginning at nucleotides 8470 and 13447, removing a region of almost 5 kb of mtDNA between ATPase 8 and the ND5 genes. The deletion is thought to occur during replication of the mtDNA. This absent arc encodes for six essential polypeptides of the respiratory chain and five tRNAs. It has been associated with several different clinical entities, including chronic progressive external ophthalmoplegia (CPEO) and Kearns-Sayre syndrome (KSS). The common deletion has also been shown to increase with age in skeletal muscle [29] [30] [31] [32] [33] , cardiac muscle [30, [34] [35] [36] , diaphragm [36] , retina [37] , skin [38, 39] , ovary [40] and sperm [41] . However it is undetectable in foetal tissues. Another mutation widely reported to increase with age in skeletal and cardiac muscle, brain and skin is a 7.4-kB deletion between np 8649 and np 16084. This deletion is also found in the muscle of some patients with CPEO and KSS. However the overall levels of individual mutations observed in aging human tissue are low (<1%) and, by analogy to the situation in patients with mtDNA diseases, it is difficult to see how individual mutations could affect mitochondrial function.
Work by Brierley et al. [42] in individual aged skeletal muscle fibres demonstrated that a clonal expansion of a single mutation (the common deletion) occurred to very high levels in a few cytochrome c oxidase (COX)-deficient fibres. High levels of clonally expanded common deletion mtDNA were not observed in fibres with preserved COX activity. They went on to suggest that other mutations could be responsible for the COX-deficient fibres not containing this one particular deletion. Recently Khrapko et al. [43] have used long polymerase chain reaction (PCR) techniques in individual cardiomyocytes from old patients to study mtDNA deletions at the single cell level. Their results indicate that various different deletions occur within different cells, but that clonal expansion of only one particular mutation occurs within an individual cell. Therefore in homogenate samples the overall level of a single mutation would be expected to be low. In aging human brain, Melov et al. [44] have observed a heterogeneous array of rearranged mtDNAs using long-extension PCR assays indicating that a similar phenomenon may also be The Mitochondrial Genome, Aging and Neurodegenerative Disorders occurring in the CNS. This accumulation of multiple mtDNA mutations in different cells would explain the low levels of individual mtDNA mutations observed in aging studies looking for single mtDNA mutations in homogenate tissue.
Accumulation of mtDNA Mutations in Age-Related and Neurodegenerative Disorders
Several age-related disorders have been shown to harbour higher levels of mtDNA mutations than their age-matched counterparts. In one study the common deletion in cardiac muscle from patients with ischaemic heart disease contained up to 240 times normal cardiac muscle deletion levels [35] . In another study by Pang et al. [38] , skin that was sun exposed in one individual had 30 times the level of common deletion than non-exposed skin. In the CNS, Ikebe et al. [28] found 17 times the level of the common deletion in the striatum of Parkinson's disease patients compared with age-matched controls. There is also evidence to show that levels of the common deletion are higher in patients with AD [45] . Levels of the oxidised nucleotide 8-OH-dG are also higher in the brains of AD patients [46] . Whether all these increases are a primary or secondary event in the pathogenesis of these diseases requires clarification.
Mitochondrial Enzyme Deficiency as a Marker of mtDNA Mutations
The presence of mtDNA dysfunction may also be examined by measuring the activities of respiratory chain complexes. Complex IV of the respiratory chain, COX, is essential for respiratory chain function. COX is composed of 13 subunits, three of which, the larger subunits, I, II, and III are encoded by mtDNA and are synthesised within the mitochondria; the remaining ten subunits are encoded by the nuclear genome. MtDNA integrity is therefore essential for the successful synthesis of active COX. However the activity of complex II, succinate dehydrogenase (SDH) remains intact despite mtDNA dysfunction since this enzyme is solely nuclear encoded. This alteration in respiratory chain enzyme activity is used for diagnostic purposes in suspected cases of mtDNA myopathy, in which skeletal muscle frequently shows a mosaic of COX-positive and COX-deficient SDH-positive fibres. Previous studies from our group have shown that the mechanism of these changes is likely to be clonal expansion of an individual mtDNA mutation within individual muscle fibres [42] .
Many studies have reported the finding of COX deficiency at a single cell level. Muller-Hocker [47] first demonstrated COX-deficient cardiomyocytes in human heart that increased with age. COX-deficient cardiomyocytes were regularly present from the sixth decade of life onwards, only occurring sporadically prior to this. It was observed that the loss of enzyme activity was always confined to single randomly distributed cardiomyocytes. The density of COX-deficient cardiomyocytes increased from an average in the third decade of life of 3 defects/cm 2 to 50 defects/cm 2 in heart aged over 70 years. Histochemical analysis of COX activity in various extra-ocular muscles also revealed randomly distributed COX-deficient fibres [48] . Defects were observed in the second decade of life in some subjects and were consistently apparent from the third decade onwards. In limb muscle and diaphragm, an almost tenfold increase in the incidence of defective fibres was noted for those in the 8th and 9th decade (54-60 defects/cm
2 ) compared to those between the 3rd and 6th (5-7 defects/cm 2 ). The affected isolated muscle fibres showed normal SDH activity [47] . These observations were confirmed by Byrne and Dennett [49] who reported an accumulation of COX-deficient fibres in the diaphragm from the 4th decade onwards, with an exponential increase in later life.
Our recent studies have concentrated on COX activity within the CNS. Both neurons and muscle are predominantly post-mitotic cells and previous studies have shown low levels of individual mtDNA deletions in aged brains. We have already shown that COX-deficient, SDH-positive neurones exist in abundance in the CNS of a patient suffering from a multiple mtDNA deletion disorder [9] . Interestingly in this case the proportion of COX-deficient neurons seems to be inversely proportional to the degree of neuropathological damage.
In addition we have completed a comprehensive study of 30 normal human brains from 0 to 87 years of age exploring whether there are COX-deficient, SDH-positive neurones in the hippocampus and epithelial cells in the adjacent choroid plexus, both structures known to be affected pathologically in aging. We found an age-related increase in COX-deficient SDH-positive hippocampal CA pyramidal neurons (Fig. 2a) and an even greater increase in COX-deficient SDH-positive choroid plexus epithelial cells (Fig. 2b) [50] . Both these CNS regions are known to show a chronologically related increase in the incidence of other pathological changes. In addition we observed that the COX-deficient SDH-positive choroid epithelial cells were associated with an increase in size. This was of particular note since a similar enlargement in the size of choroid epithelial cells has been described in mtDNA disorders [51, 52] . The swelling of these choroidal cells in the mtDNA disorders was seen to be due to a massive proliferation of abnormal looking mitochondria on electron microscopy [52] .
We have just completed a similar study comparing AD brains with agematched controls. Unpublished results show an increased incidence of COXdeficient SDH-positive hippocampal neurons and choroidal epithelial cells in the AD cases. We believe that this is the first direct evidence to show that a mitochondrial defect can occur in individual neurons to such an extent to cause an actual biochemical deficiency in AD. The role these COXdeficient neurons play in the pathogenesis of AD requires further study. We aim to directly examine the correlation between these COX-deficient neurons with the established pathological changes of AD, amyloid plaques and neurofibrillary tangles. We also wish to address whether neurons that become COX-deficient undergo neurodegeneration using immuno-labelling for apoptotic markers since mitochondria appear to play such a pivotal role in apoptotic mechanisms [53] .
Molecular studies have concentrated on single-cell mtDNA analysis. Individual cells can be extracted by micropipette manipulation and their mtDNA analysed using various PCR techniques. Competitive three primer PCR for the common deletion has shown very high levels of this deletion in several individual COX-deficient choroid plexus epithelial cells (unpublished results). This indicates that clonal expansion of a single mutation can occur within a single cell. The mutated form of mtDNA appears to have gained a replicative advantage over the wild type perhaps via favourable replicative or degenerative conditions. We are currently working on establishing other types of PCR and sequencing in single neurones to look at other deletions and point mutations.
Mitochondria and Cellular Dysfunction and Death
There is now little doubt that mitochondria accumulate deleterious changes with time, but how these changes are related to the aging process remains a challenge. Mitochondria, however, being essential for the production of the majority of the cell's ATP production, do possess several potential means of causing cellular dysfunction and death.
Disrupting the mitochondrial respiratory chain and consequently energy metabolism has long been recognised as an early feature of cell death. ATP production is essential to many cellular processes, including the maintenance of transmembrane potential via ATP-dependent ionic pumps. Therefore, a drop in ATP production is a likely cause of cellular dysfunction and perhaps even death, which, unlike apoptosis, is not ATP-dependent. As described above, defects in the respiratory chain have been reported in aging studies, and this may contribute to some of the pathogenesis observed in aging. Inhibition of the respiratory chain also results in an increase in the rate of free radical production. Free radicals have been linked with apoptosis, but it is also believed that they can directly cause damage to proteins, lipids, and DNA. By altering their structural configurations, and by an age-related increase in free radical generation coupled with a decrease in free radical-scavenging enzymes, age may impair cellular function, leading to a vicious circle culminating in cell death.
The Mitochondrial Genome, Aging and Neurodegenerative Disorders Mitochondria are now also known to play a pivotal role in the complex pathways of apoptosis [53] . They contain both apoptotic cascade inhibitors (BCL-2) and activators (cytochrome c and apoptosis-inducing factor). It is widely believed that activation of the mitochondrial transition pore, a large non-selective conductance channel located in both the inner and outer mitochondrial membranes, may be central to the apoptotic process. The opening of the transition pore is triggered by an increase in intracellular calcium and reactive oxygen species, resulting in a fall in the transmembrane mitochondrial potential and a volume dysregulation caused by the hyperosmolarity of the mitochondrial matrix. The matrix space expands, eventually resulting in membrane rupture with the release of the pro-apoptotic cytochrome c, which activates the cytosolic caspase-mediated degradation pathway, and apoptosis-inducing factor, which promotes nuclear chromatin destruction. Indeed, pharmacological inhibitors of the transition pore, such as cyclosporin, have been reported to prevent apoptosis by several direct stimuli [54] .
A greater understanding in the role that mitochondria play in cellular dysfunction and death may therefore elucidate new strategies for the pharmaceutical industry to explore in both aging and many age-related disorders.
Discussion
Dr. Rosenberg: As many of us are not as familiar with the mitochondrial DNA mutations as with nuclear ones, can you tell us something more about the relation between the two? Are there circumstances where there is an increased amount of DNA nuclear mutation, and is this correlated in any way with the amount of mitochondrial mutation, and is there any functional cross-talk?
The Mitochondrial Genome, Aging and Neurodegenerative Disorders Dr. Cottrell: There is a lot of cross-talk between mitochondrial DNA and nuclear DNA. Over evolution, the mitochondrial genome has shrunk. If you go back in evolution, mitochondrial DNA was much larger -10, 20, 100, 1,000 times, depending on the stage of evolution you are looking at -and it appears that the reason why the genome has shrunk is that the mitochondria have become lazy, if you like. They have transposed the DNA from the mitochondria into the nuclear DNA. So if you look at plants, for instance, you will find mitochondrial genes that are similar to nuclear genes in mammalian species, so it seems that over time some genes, including those for the oxidative phosphorylation chain and other proteins for the mitochondria, have been moved from the mitochondrial DNA genome to the nuclear DNA genome. Without doubt nuclear genome mutations can cause accelerated mutations in mitochondrial DNA. The case where I showed the histochemistry of the mitochondrial DNA was a multiple deletion disorder. I chose that case as it is a particularly good model for aging in that the defect is not a mitochondrial DNA defect but a nuclear DNA defect which appears to cause an acceleration in the number of deletions in the mitochondrial DNA genome. There are other mitochondrial DNA disorders that are autosomally inherited, not maternally inherited, indicating that there is definite cross-talk between the two genomes.
Dr. Rosenberg: I am fascinated by the choroid plexus observation because, as you and others know, the choroid plexus has a lot to do with the transport of nutrients, including vitamins, across the blood-brain barrier. As some of the changes with aging may have to do with B vitamin function, let's say in the brain, is it possible that these choroid plexus changes that you observed with the COX-negative cells have an effect on the transport function of the choroid plexus in the blood-brain barrier?
Dr. Cottrell: I think that is a very important question. As you point out, the choroid plexus is an essential part of the blood-brain barrier and the choroid plexus cells contain very high levels of mitochondria -perhaps the highest of any human cell at around 13-15% of the cytoplasmic volume. This suggests that they are very highly energy-dependent and they also have a lot of transport mechanisms for moving substances into and out of the brain. So if we can show that these cells are energydeficient that will be very important. The other important thing about the choroid plexus is that it is a single cell barrier, so if you have one COX-deficient cell, could that be a cause of leakiness within the barrier? I think the choroid plexus findings are a lot more important than the findings we are seeing in neurons, so they demand a great deal of further investigation.
Dr. Taylor: Could you make the distinction between correlation and causality? Your research would be so much more valuable if you could determine causality.
Dr. Cottrell: That is vital. That is why we have tried to do those studies with apoptosis and neuropathological markers. To date we still have not found what is happening to the COX-deficient neurons or the COX-deficient choroid plexus cells. We are trying to do this by going back and looking at the mitochondrial DNA disorders. These disorders have high levels of COX-deficient cells and show a great deal of neuropathology, in particular neuronal loss. There appear to be no other neuropathological markers. The main changes are neural dropout and the accompanying demyelination -there are no plaques, no tangles, and no inclusion bodies within those cells, and the only other positive findings are obtained using this histochemical technique. So, although we have not shown this directly, we think that COX deficiency must be contributing to the neuronal loss.
Dr. Taylor: But couldn't you do something like a simple mutation analysis? Dr. Cottrell: We are trying to do that with neuronal stem cell cultures to see if we can introduce different levels of mitochondrial DNA mutations into those cultures and then expose them to stresses to see if they survive. We would be delighted if anyone else, with their expertise, would like to try that. I think it would be very useful. We
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Dr. Meydani: I wonder how much of the correlation with COX deficiency is connected with maturation rather than aging.
Dr. Cottrell: I agree there seems to be a threshold in the late 30s when these COX-deficient neurons occur, and if you cut off the graph at that stage you lose the statistically significant correlation. I certainly accept that. However, in the choroid plexus it is a different story. You start to see COX-deficient cells at a much earlier stage, in the teens, and these then accumulate progressively. It seems that the choroid plexus manifestations occur first, before the hippocampal manifestations, so perhaps, as I mentioned earlier, this could cause a leakiness of the blood-brain barrier which would then go on to produce damage in the central nervous system. Dr. Roubenoff: There is a short but growing list of drugs that are thought to be mitochondrial toxins. Is there any evidence about whether cells from aged people are more susceptible to that toxicity, and if so would you care to explain the mechanisms by which that might happen?
Dr. Cottrell: I am not aware of work being done on that, but if we go back to the situation of heteroplasmy then you would expect that to be the case. If there is an accumulation of mitochondrial DNA mutations as you get older, then you would need less toxin within the cell for a harmful effect, because there is less mitochondrial DNA to encode for protein subunits. So I would image that, particularly if there is a competitive antagonism of the respiratory chain, the mitochondrial DNA might not be up to the task in an aging population of cells.
Dr. Endres: Do you have any experience of treating patients with mitochondrial DNA disorders with thiamine or riboflavin or other substances affecting the respiratory chain?
Dr. Cottrell: As I tried to point out, these patients show great variety in their symptoms and in the severity of their disease. To date there is no chemical scoring system for these patients. I have been involved in the epidemiology of multiple sclerosis and we now have a very nice scoring system for that disease -the EDSS -where you can look at the natural history of the disease and predict who will be in a wheelchair in, say, 6 years. We need a similar scoring method for mitochondrial DNA disorders so that we can look at their natural history before we start using vitamins and drugs to treat them. We do treat our patients with coenzyme Q but how can you tell if it works or not? That is impossible in the present state of our knowledge because of the fluctuating nature of the symptoms, though it makes us feel better to treat the patients with something. We need to have a good natural history database and a good scoring system. We are now in a strong position to achieve those ends because we have a database of hundreds of patients. What we need to do now is to put our heads together and devise a scoring method before doing further studies involving treatment.
Dr. Weindruch: I have a question and a comment, recently published in the FASEB Journal [1] . They used laser capture techniques in aging rodent skeletal muscle and showed that there were mitochondrial DNA deletions in the ETS-abnormal fibers. When the fibers were followed longitudinally, the mitochondrial DNA deletions were linked to fiber atrophy, showing a possible molecular basis for that outcome.
My question relates to the broader picture of the mitochondrial contribution to the aging process. The piece of evidence that I am underwhelmed by so far from my searches in the literature -though maybe you have found papers that I haven't -concerns the predicted reduction in ATP levels due to the mitochondrial abnormalities. Have you found convincing evidence that ATP levels in postmitotic tissues decline with aging?
Dr. Cottrell: I have seen no papers on that, but Porteous et al. [2] has done studies on cultured cells with different levels of mutation and found a significant fall in the The Mitochondrial Genome, Aging and Neurodegenerative Disorders mitochondrial membrane potential. If I remember correctly, he also showed a decrease in the ATP-producing capability.
In relation to the muscle studies you were referring to, there have also been two papers on apoptotic labeling in mitochondrial encephalomyopathies [3] . These both looked at a series of patients to see whether there was evidence of apoptosis in the muscle fibers. They did very similar studies using similar antibodies and got completely different results. One group found that a high percentage of the muscle fibers showed signs of apoptosis [4] , while the other group found none at all [3] .
Dr. Weindruch: Don't you have fears about the levels of oxygen that cells are exposed to in culture studies, in terms of studying these phenomena?
Dr. Cottrell: Cultured cells are not ideal but neuropathological studies may also be less than ideal. We have to go with what we have.
Dr. Rosenberg: Are there known mechanisms for correction of mutations, and are the usual systems for DNA repair very different in mitochondrial DNA?
Dr. Cottrell: There is a lot of controversy about mitochondrial DNA. It was initially thought that mitochondria contain very little in the way of mitochondrial or DNA repair mechanisms, but that view has come under fire recently and some people believe that there are some DNA repair mechanisms in mitochondria. However, overall it is believed that they have a less efficient means of repair.
Dr. Arnaud: Are the findings the same in different mammalian species? Dr. Cottrell: In our group, Blakely has been doing a similar study in mice and Professor Tom Kirkwood has also brought his murine models of aging to Newcastle. It does appear that there are COX-deficient neurons in mice, and it would be interesting to look at other animals as well.
Dr. Weindruch: A group in Spain and another in the USA have looked at isolated mitochondria from multiple species. They have found that long-lived species have lower rates of production of reactive oxygen species. This may provide some insight into the paradox of why birds live so long.
Dr. Rosenberg: As there is so much interest in antioxidants and the aging process, perhaps one of the next targets has to be how to increase the antioxidant status in the mitochondria, not just in other parts of the organelles and the cell.
Dr. Cottrell: That's a good point, though it is possible that oxygen free radicals may not be wholly damaging -perhaps they have some other role as well, for example they could have a role as a messenger system in the cells. In that case there could be a down side to giving free radical scavengers. We need to proceed with caution.
